2don MSN
Rallybio shares successful early-stage results for rare disease drug; new trial set for late 2026
Rallybio Corporation RLYB on Tuesday shared results from its Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) clinical trial of RLYB116 for complement-mediated diseases, with its initial ...
From football players to military personnel, people who suffer repeated head injuries often face serious long-term health issues. These include problems with memory, mood, and movement, and in some ...
A protein made by stressed cancer cells helps lung and pancreatic tumors evade the immune system, a new study shows. Led by researchers from NYU Langone Health, the work found that new drugs designed ...
Your immune system is like an incredibly sophisticated security team, constantly patrolling your body for threats and neutralizing them before they can cause harm. When it’s working properly, this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results